Loading organizations...
Founded in 2022 by Chief Executive Officer Jean-Marc Herbert, Abcely is a Nantes, France-based biotechnology company developing specialized anti-cancer medications and innovative pharmaceutical technologies specifically designed for treating mucosal cancers. To support its ongoing research and clinical development pipeline, the four-employee enterprise successfully secured €2.4 million in a combination of public and private fundraising during 2023. Operating within the broader health technology sector to create novel therapeutic options for oncology patients, the startup's therapeutic initiatives are actively supported by the MATWIN oncology innovation program. The executive leadership team includes Chief Technology Officer Olivier Favre-Bulle and Béatrice Lejeune, who collaborate to advance the firm's specialized medical technologies. Furthermore, the organization's scientific advisory board features prominent medical researchers such as Professor S Paul, Professor M Van Egmond, and Professor M Ducreux to guide its clinical strategies.
Abcely has raised $3.0M across 1 funding round.
Abcely has raised $3.0M in total across 1 funding round.
Abcely has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2023 | $3M Seed | — | GO Capital | Announced |
Abcely has raised $3.0M in total across 1 funding round.
Abcely's investors include Go Capital.
Abcely is a biotechnology company developing the world's first platform for orally active secretory IgA (sIgA)-based immunotherapy, targeting mucosal cancers and chronic mucosal diseases.[1][2] It addresses limitations of traditional IgG therapies by creating mucosal-targeted oral treatments, with a scalable pipeline enabling rapid out-licensing and value inflection points in high-need oncology markets.[1] Abcely serves patients with mucosal cancers, solving unmet needs through first-in-class proprietary sIgA assets produced in under 8-9 months from target identification to preclinical validation, de-risking development and accelerating market entry with no direct competition.[1][6]
Abcely emerged from a mission to innovate in mucosal cancer treatments, inspired by the profound impact of cancer diagnoses—likened to a "tsunami" that shatters lives, with their logo drawing from Japanese kintsugi tradition of repairing ceramics with gold to highlight and sublimate scars.[1] While specific founders and founding year are not detailed in available sources, the company is associated with biotherapy ecosystems like Atlanpole Biotherapies, indicating early ties to French biotech clusters.[4] Pivotal early focus centered on engineering a proprietary sIgA platform via CDR grafting technology, enabling quick optimization of biologic candidates and strategic partnerships.[1]
Abcely rides the wave of precision biologics and mucosal immunotherapy trends, capitalizing on growing demand for targeted oral treatments in oncology where traditional IV IgG therapies fall short for mucosal sites like oral, gastrointestinal, and respiratory cancers.[1] Timing aligns with advances in antibody engineering and unmet needs in high-value markets, amplified by post-pandemic focus on scalable, patient-friendly delivery methods.[1] Market forces favoring biologics innovation—rising cancer incidence and biologics market expansion—position Abcely to influence the ecosystem through out-licensing, fostering faster innovation cycles and potential shifts toward oral mucosal therapies.[1][5]
Abcely's trajectory points to preclinical milestones, partnership expansions, and licensing deals as near-term catalysts, leveraging its de-risked platform for multiple exits in oncology.[1] Trends like AI-accelerated drug discovery and mucosal vaccine tech will shape its path, potentially amplifying influence as oral biologics gain traction amid IgG patent cliffs. As a differentiator in a crowded biotech space, Abcely could redefine mucosal cancer care, turning diagnostic "tsunamis" into rebuilt lives.[1]
